Conferences
ORBITA Trial & Panel Discussion Dr. Kirk Garratt, Dr. Ajay Kirtane and Dr. C. Michael Gibson Discuss
SWAP 4 trial: De-escalation of P2Y12 Inhibitors
In a recent article published in The Circulation, it has been found that the use of a loading dose while switching between P2Y12 inhibitors in patients with coronary artery disease is associated with mitigation of the reactivity of platelets. The study has also emphasized that timing of administration of loading dose has no impact on platelet reactivity.
HeartMate 3: Magnetic Pump in Advanced Heart Failure
According to a new study published in the New England Journal of Medicine, a fully magnetically levitated centrifugal- flow pump has been found to be superior to a mechanical-bearing axial-flow pump in advanced heart failure patients in terms of survival free of disabling stroke or reoperation for removal in case of device malfunction.
VEST: Wearable cardiac defibrillator decreases mortality post MI
The first randomized trial of the Wearable Cardiac Defibrillator (WCD) was conducted by Dr. Jeffrey Olgin and his colleagues from the University of California and presented at the ACC 2018 in Orlando, Florida. The trial showed that prescribing the WCD was reasonable to protect high-risk patients with a low LVEF (Left ventricular ejection fraction) post-MI until evaluation for an ICD at 40-90 days.
Febuxostat Non-Inferior to Allopurinol in Reduction of MACE but Increases Mortality
In a recent article, published in The New England Journal of Medicine, the rates of major cardiovascular events with febuxosat were similar to allopurinol in patients with gout and concomitant cardiovascular disease. However, the mortality rates either due to cardiovascular deaths or any other cause were higher with febuxostat than allopurinol. Continue reading
TRIUMPH: Low-dose Triple-Combination BP Lowering for Hypertension Dr. Webster and Dr. Gibson Discuss
